ANGLE plc (GB:AGL) has released an update.
ANGLE plc has unveiled promising new data at the AACR Special Conference, highlighting its Parsortix-based PD-L1 assay’s potential in improving personalized treatment for lung cancer patients. This innovative liquid biopsy technology enables non-invasive, ongoing monitoring of PD-L1 status in circulating tumor cells, which could offer a more dynamic and comprehensive assessment of tumor heterogeneity compared to traditional tissue biopsies.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
